Published in Pharm Pract (Granada) on March 10, 2008
Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. J Multidiscip Healthc (2012) 0.78
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23
Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA (2003) 14.72
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med (1994) 10.26
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med (1999) 7.74
Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med (2006) 5.58
Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med (2000) 5.41
Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med (1998) 3.91
Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med (2000) 3.60
Practical clinical trials for translating research to practice: design and measurement recommendations. Med Care (2005) 3.38
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.11
Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med (1991) 2.72
Antithrombotic therapy in atrial fibrillation. Chest (2001) 2.62
A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess (2005) 2.42
Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med (2005) 2.32
Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke (2000) 2.29
Warfarin use among patients with atrial fibrillation. Stroke (1997) 2.23
Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med (1997) 2.01
Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med (1995) 2.00
Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol (2002) 1.92
Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest (2005) 1.90
Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. Stroke (1997) 1.89
Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation (2005) 1.66
Randomised trial of two approaches to screening for atrial fibrillation in UK general practice. Br J Gen Pract (2002) 1.64
Antithrombotic prescribing in atrial fibrillation: application of a prescribing indicator and multidisciplinary feedback to improve prescribing. Age Ageing (2002) 1.55
Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan. J Med Screen (2004) 1.45
Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy (1996) 1.35
Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med (1998) 1.33
Nine-year experience with a pharmacist-managed anticoagulation clinic. Am J Hosp Pharm (1986) 1.32
The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Can J Cardiol (2003) 1.25
Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist-managed anticoagulation service. Pharmacotherapy (2005) 1.20
Evaluation of a pharmacy-managed warfarin-monitoring service to coordinate inpatient and outpatient therapy. Am J Hosp Pharm (1992) 1.19
Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic. J Am Board Fam Pract (2001) 1.18
Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. Am J Manag Care (2004) 1.17
Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ (2001) 1.13
An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care (2004) 1.11
Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm (1985) 1.08
Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J Am Geriatr Soc (2005) 1.03
An outreach intervention to implement evidence based practice in residential care: a randomized controlled trial [ISRCTN67855475]. BMC Health Serv Res (2004) 1.02
The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy (1989) 1.00
Effect of access to anticoagulation management services on warfarin use in patients with atrial fibrillation. Pharmacotherapy (2005) 0.88
Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol (1991) 0.86
A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation. Ann Pharmacother (2004) 0.81
Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions. Am J Health Syst Pharm (1996) 0.80
Anticoagulation and atrial fibrillation. Herz (1993) 0.80
A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE) [ISRCTN19633732]. BMC Cardiovasc Disord (2004) 0.78
Efficacy of anticoagulation for stroke prevention and risk stratification in atrial fibrillation: translating trials into clinical practice. Am J Manag Care (2004) 0.77
Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke. Am J Geriatr Pharmacother (2004) 0.77